Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First-line Treatment Failure Nasopharyngeal Carcinoma”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)UnknownNCT04586088
What this trial is testing

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Who this might be right for
Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaMetastatic Nasopharyngeal Carcinoma+3 more
Sun Yat-sen University 58
Testing effectiveness (Phase 2)Study completedNCT00747799
What this trial is testing

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Who this might be right for
Nasopharyngeal Neoplasms
Sun Yat-sen University 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT06414577
What this trial is testing

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Who this might be right for
Nasopharyngeal Cancer
XIANG YANQUN 38
Testing effectiveness (Phase 2)Looking for participantsNCT07101744
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Who this might be right for
Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University 41